AAX Biotech develops next-generation antibody platforms that address key limitations in therapeutic antibody discovery and design. Its proprietary technologies – Seqitope® and Opti-mAb® – are engineered to enhance epitope resolution, antibody stability and manufacturability, enabling more effective drug candidates in areas such as bispecific antibodies and CAR-T therapies.
Dr. Ionut Gabriel Dumitru, an expert in next-generation sequencing, bioinformatics, and antibody engineering, joins AAX to lead both customer-focused and internal R&D initiatives. With this strong background, he will play a key role in advancing the company’s technology platforms and driving continued innovation in epitope mapping.
Dr. Kushal Sejwal brings over a decade of experience at the intersection of science and strategy, having led commercialization efforts in structural biology and cryo-electron microscopy. At AAX Biotech, he will focus on strategic partnerships and business growth to accelerate the adoption of the company’s antibody technologies.
“We’re seeing strong and growing interest in our Seqitope® and Opti-mAb® platforms, which is driving momentum for the company. Strengthening both our R&D and commercial teams is a natural next step, and I’m very pleased to welcome Ionut and Kushal to AAX Biotech,” says Maria Lisa Knudsen, CEO.
Ionut Gabriel Dumitru comments: “I am excited to join AAX and contribute to advancing its innovative technologies, integrating protein biology with cutting-edge robotics and machine learning”.
Kushal Sejwal also comments: “I am looking forward to contributing to AAX’s growth by building strong collaborations and expanding the reach of Seqitope® and Opti-mAb® in the rapidly evolving field of antibody therapeutics.”
The team expansion aligns with AAX’s broader mission to enhance its capabilities in both research and business development, ensuring the company is well-positioned to drive innovation and scale its impact in the biotech industry.
About AAX Biotech AB
AAX Biotech AB is a biotech company specializing in next-generation antibody therapeutics. The company offers two unique and proprietary technologies, Seqitope® and Opti-mAb®, that enable high throughput and high-resolution epitope mapping as well as stabilization of single chain variable fragments (scFv) for applications such as bispecific antibodies and CAR-T cells. Both technologies aim to produce better and more effective antibody-based medicines. These innovations position AAX Biotech as a key player in the rapidly growing antibody therapeutics market. AAX Biotech is founded by experts from Karolinska Institutet in Stockholm, Sweden. Visit aaxbiotech.com to learn more and follow AAX Biotech on LinkedIn.
